Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis

Juliana M. F. Silva,1 Fani Ladomenou,1 Ben Carpenter,2 Sharat Chandra,3,4 Petr Sediłcek,5 Renata Formankova,5 Vicky Grandage,2 Mark Friswell,6,7 Andrew J. Cant,6,7 Zohreh Nademi,6,7 Mary A. Slatter,6,7 Andrew R. Gennerly,6,7 Sophie Hambleton,6,7 Terence J. Flood,6,7 Giovanna Lucchini,1 Robert Chiesa,1 Kanchan Rao,1 Persis J. Amrolia,1 Paul Brogan,8 Lucy R. Wedderburn,8,9 Julie M. Glanville,1 Rachael Hough,2 Rebecca Marsh,3,4 Mario Abinun,6,7 and Paul Veys1

1Department of BMT, Great Ormond Street Hospital for Children, National Health Service (NHS) Foundation Trust, London, United Kingdom; 2Department of Adolescent BMT, University College Hospital, NHS Foundation Trust, London, United Kingdom; 3Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; 4Department of Pediatrics, University of Cincinnati, Cincinnati, OH; 5Department of Pediatric Hematology and Oncology, Teaching Hospital Motol, Prague, Czech Republic; 6Great North Children’s Hospital, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom; 7Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; 8Department of Rheumatology, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom; and 9University College London Great Ormond Street Institute of Child Health and NIHR GOSH Biomedical Research Centre, NHS Trust, London, United Kingdom

Key Points

• Allo-HSCT using reduced intensity conditioning with alemtuzumab appears to be effective and safe for patients with refractory JIA.
• Early allo-HSCT may prevent joint damage, reduce toxicity associated with immunosuppression, and reduce transplant-related mortality.

Patients with juvenile idiopathic arthritis (JIA) can experience a severe disease course, with progressive destructive polyarthritis refractory to conventional therapy with disease-modifying antirheumatic drugs including biologics, as well as life-threatening complications including macrophage activation syndrome (MAS). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative immunomodulatory strategy for patients with such refractory disease. We treated 16 patients in 5 transplant centers between 2007 and 2016: 11 children with systemic JIA and 5 with rheumatoid factor–negative polyarticular JIA; all were either refractory to standard therapy, had developed secondary hemophagocytic lymphohistiocytosis/MAS poorly responsive to treatment, or had failed autologous HSCT. All children received reduced toxicity fludarabine-based conditioning regimens and serotherapy with alemtuzumab. Fourteen of 16 patients are alive with a median follow-up of 29 months (range, 2.8–96 months). All patients had hematological recovery. Three patients had grade II-IV acute graft-versus-host disease. The incidence of viral infections after HSCT was high, likely due to the use of alemtuzumab in already heavily immunosuppressed patients. All patients had significant improvement of arthritis, resolution of MAS, and improved quality of life early following allo-HSCT; most importantly, 11 children achieved complete drug-free remission at the last follow-up. Allo-HSCT using alemtuzumab and reduced toxicity conditioning is a promising therapeutic option for patients with JIA refractory to conventional therapy and/or complicated by MAS. Long-term follow-up is required to ascertain whether disease control following HSCT continues indefinitely.

Introduction

Systemic juvenile idiopathic arthritis (sJIA) is characterized by arthritis associated with prominent systemic features such as fever, skin rash, serositis, lymphadenopathy, hepatosplenomegaly, and increased inflammatory markers. Clinical outcome is generally poor if symptoms are not well controlled1,2; ~10% of patients with sJIA develop life-threatening complications such as macrophage

© 2018 by The American Society of Hematology

10 APRIL 2018 • VOLUME 2, NUMBER 7 777
activation syndrome (MAS), which has a reported mortality of 8% in this context, and/or severe life-threatening infections due to prolonged immunosuppressive treatment with multiple agents.3,6

The main goal of immunosuppressive and anti-inflammatory treatment strategies in sJIA is to achieve disease remission while trying to minimize drug-related toxicity. There are multiple treatment options, including nonsteroidal anti-inflammatory drugs, corticosteroids, disease-modifying antirheumatic drugs (DMARDs) such as methotrexate (MTX), and a variety of biologics targeting key inflammatory cytokines.7 Although most children with sJIA respond to conventional therapy, a small proportion of patients either do not achieve disease remission or experience significant drug-related side effects.8 This can lead to long-term sequelae including permanent joint damage, osteoporosis, growth retardation, and reduced quality of life.7,9

Autologous hematopoietic stem cell transplantation (HSCT) has been assessed as a therapeutic option for children with refractory sJIA since 1997, as an experimental strategy to reset the dysregulated immune system and eliminate autoreactive T cells.9 A number of studies have demonstrated that children undergoing a T-cell–depleted autologous HSCT for refractory JIA, majority with sJIA, can achieve complete drug-free remission.10-14 However, in some cases, disease remission is of transient duration, as a significant proportion of children relapse with inflammatory symptoms after autologous transplant, probably due to reemerging autoreactive T lymphocytes.15 Moreover, T-cell–depleted autologous HSCT is associated with significant mortality, due to prolonged and severe depression of T-cell immunity, leading to viral infections and MAS.11-13

Allogeneic HSCT (allo-HSCT) has potential advantages in this context, with the goal of achieving life-long disease remissions by replacement of the patients’ dysregulated immune system.16,17 Conversely, allo-HSCT introduces the significant risk of graft-versus-host-disease (GVHD). Data on allo-HSCT performed in children with autoimmune diseases and in particular JIA, are extremely scarce.18-20 Here, we report the outcomes of 16 children with severe, refractory JIA who underwent allo-HSCT in 5 different centers between 2007 and 2016.

Methods

Patients and methods

This retrospective observational cohort describes the outcomes of 16 children with refractory JIA: 11 children with sJIA and 5 with rheumatoid factor (RF)-negative polyarticular JIA (poly-JIA) who underwent allo-HSCT in 5 different centers between April 2007 and March 2016. The centers participating in this study were Great Ormond Street Hospital, London, United Kingdom (n = 5); Great North Children’s Hospital, Newcastle upon Tyne, United Kingdom (n = 5); University College Hospital, London, United Kingdom (n = 2); Teaching Hospital Motol, Prague, Czech Republic (n = 1); and Cincinnati Children’s Hospital Medical Center (CCHMC), Cincinnati, OH (n = 3). Medical charts were reviewed and the following data were extracted from each case using a standardized form: patient demographics, classification of JIA subtype, treatments prior to HSCT, indication for HSCT, donor-recipient matching, conditioning regimen, and graft composition. Posttransplantation data were collected on count recovery, immune reconstitution, lineage-specific chimerism, occurrence of GVHD, infections, and relapse of initial (or occurrence of new, secondary, post-HSCT) autoimmunity. All patients were enrolled in their local institutional review board–approved protocol or treatment plan. Written informed consent was obtained from the parents or legal guardians of all patients prior to the initiation of conditioning therapy for transplantation. Information regarding patient 1 has been previously published.12

Data are presented in terms of frequency and central tendency measures (means and medians). All patients had HLA medium- or high-resolution typing for the following loci: class I (HLA A, B, C) and class II (HLA DQ, DRB1). Patients were considered refractory to treatment if they had active disease that failed to respond to multiple lines of treatment including 2 or more biologics or unacceptable adverse reaction to corticosteroids or biologics.

Complete response (CR) post-HSCT was defined as complete resolution of arthralgia or arthritis and no recurrence of disease symptoms after stopping immunosuppression (IS). Partial response (PR) was defined as: (1) significant clinical improvement and off IS or (2) complete resolution of inflammatory symptoms, but ongoing IS.

Results

Patient characteristics

Patients’ characteristics are summarized in Table 1. The median age at diagnosis was 21.5 months (range, 5 months to 12 years), whereas the median age at transplant was 8.4 years (range, 2.6-16 years). Patients received a median of 5 (range, 2-9) lines of immunomodulatory treatment before HSCT, specifically 9 of them received tocilizumab, and all children were considered refractory to treatment. Five patients had suffered life-threatening complications pre-HSCT. Indication for transplant was: (1) unresponsiveness to standard therapy and biologics (n = 10), (2) failed autologous stem cell transplant (n = 1), or (3) secondary hemophagocytic lymphohistiocytosis (HLH)/MAS, poorly responsive to treatment (n = 5). None of the patients with MAS had a molecular diagnosis of familial HLH.

Transplant procedure

Transplant characteristics are summarized in Table 2. Patients underwent allo-HSCT from a 10 of 10 or 12 of 12 HLA matched unrelated donor (n = 9), 9 of 10 HLA mismatched unrelated donor (n = 3), or 10 of 10 HLA matched sibling donor (n = 4). All patients received a reduced toxicity conditioning regimen with fludarabine 30 mg/m² per day (from days 7 to 3), melphalan 140 mg/m² (day 3), alemtuzumab 0.2 mg/kg per day (from days 8 to 4) (n = 10) or fludarabine 30 mg/m² per day (from days 7 to 3), treosulfan 14 g/m² per day (from days 6 to 4), alemtuzumab 0.2 mg/kg per day (from days 8 to 4) (n = 6). Of the CCHMC patients, patient 2 received alemtuzumab 0.2 mg/kg per day, days 22 to 18, whereas patients 13 and 14 received it days 14 to 10. All 3 patients received fludarabine 30 mg/m² per day from days 8 to 4 and melphalan 140 mg/m² on day 3. Peripheral blood was the stem cell source in the majority of cases (n = 12).

Most patients received cyclosporine (CsA) and mycophenolate mofetil (MMF) as GVHD prophylaxis (n = 10). All patients received antiviral, antifungal, and antibacterial prophylaxis during transplant according to the local policies. The median CD34+ cell dose infused was 9.2 × 10⁶/kg (range, 1.7-32.2 × 10⁶/kg) and the median CD3+ cell dose was 3.2 × 10⁹/kg (range, 0.26-15.5 × 10⁹/kg).
<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Year of HSCT/Center</th>
<th>Sex</th>
<th>Onset type</th>
<th>Age at onset</th>
<th>Age at HSCT</th>
<th>Treatment pre-HSCT</th>
<th>Comorbidities associated with JIA treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2007/GOSH</td>
<td>F</td>
<td>Poly-JIA (RF⁺)</td>
<td>24 mo</td>
<td>10 y 1 mo</td>
<td>ASCT, MTX, CsA, etanercept, tocilizumab, anakinra, thalidomide, FK506</td>
<td>Growth failure on growth hormone</td>
</tr>
<tr>
<td>2</td>
<td>2009/CCHMC</td>
<td>F</td>
<td>sJIA + MAS</td>
<td>36 mo</td>
<td>4 y 6 mo</td>
<td>Corticosteroids, CsA</td>
<td>Obesity due to corticosteroids excess, MAS</td>
</tr>
<tr>
<td>3</td>
<td>2009/GOSH</td>
<td>F</td>
<td>sJIA + MAS</td>
<td>5 mo</td>
<td>2 y 8 mo</td>
<td>MTX, corticosteroids, anakinra, CsA, infliximab</td>
<td>CMV viremia</td>
</tr>
<tr>
<td>4</td>
<td>2010/GOSH</td>
<td>F</td>
<td>sJIA + MAS</td>
<td>5 y 7 mo</td>
<td>7 y 8 mo</td>
<td>Etoposide, CsA, corticosteroids, anakinra, ATG</td>
<td>Adenoviremia, poor left ventricular function with EF of 20% + pericardial effusion. Had 2 PICU admissions: 1. cardiac failure at presentation of MAS and 2. Pseudomonas sepsis</td>
</tr>
<tr>
<td>5</td>
<td>2012/N</td>
<td>F</td>
<td>Poly-JIA (RF⁺)</td>
<td>10 mo</td>
<td>13 y 3 mo</td>
<td>Corticosteroids, MTX, MMF, etanercept, infliximab, adalimumab, abatacept, anakinra, rituximab</td>
<td>Severe corticosteroids-related toxicity (osteoarthritis with multiple vertebral crush fractures, hypertension features, right eye glaucoma and cataract surgery), poor QOL</td>
</tr>
<tr>
<td>6</td>
<td>2014/N</td>
<td>M</td>
<td>Poly-JIA (RF⁺)</td>
<td>19 mo</td>
<td>3 y 3 mo</td>
<td>Corticosteroids, MTX, infliximab, immunoglobulin replacement</td>
<td>Undefined primary immunodeficiency early childhood interstitial pneumonitis (biopsy proven, PICU, home O2), colitis, hypogammaglobulinemia, skin rashes, nail dystrophy, fevers (no underlying mutation found so far)</td>
</tr>
<tr>
<td>7</td>
<td>2014/N</td>
<td>F</td>
<td>sJIA</td>
<td>24 mo</td>
<td>65 y</td>
<td>Corticosteroids, MTX, tocilizumab, infliximab, MTX, anakinra</td>
<td>Corticosteroids-related growth failure, cushingoid features, poor QOL</td>
</tr>
<tr>
<td>8</td>
<td>2014/UCLH</td>
<td>M</td>
<td>Poly-JIA (RF⁺)</td>
<td>18 mo</td>
<td>16 y 9 mo</td>
<td>Corticosteroids, MTX, adalimumab, abatacept, tocilizumab</td>
<td>Joint destruction due to refractory disease</td>
</tr>
<tr>
<td>9</td>
<td>2014/GOSH</td>
<td>M</td>
<td>sJIA + MAS</td>
<td>14 mo</td>
<td>6 y 2 mo</td>
<td>MTX, high-dose corticosteroids, anakinra, tocilizumab</td>
<td>Chest infection + pleural effusion requiring mechanical ventilation, Seizures secondary to steroid induced hypertensive encephalopathy, MAS</td>
</tr>
<tr>
<td>10</td>
<td>2014/UCLH</td>
<td>M</td>
<td>sJIA</td>
<td>18 mo</td>
<td>16 y 9 mo</td>
<td>Infliximab (allergic), tocilizumab, canakinumab, MTX</td>
<td>MAS, renal impairment due to ciclesonide, osteoporosis, casts, renal stones, warts, growth and pubertal delay (but coexistent Klinefelter syndrome)</td>
</tr>
<tr>
<td>11</td>
<td>2014/GOSH</td>
<td>F</td>
<td>sJIA + MAS</td>
<td>12 y</td>
<td>13 y 3 mo</td>
<td>Corticosteroids, CsA, anakinra</td>
<td>Mild left ventricular dysfunction, FS: 23%, MAS</td>
</tr>
<tr>
<td>12</td>
<td>2014/Prague</td>
<td>F</td>
<td>Poly-JIA (RF⁺)</td>
<td>4 y</td>
<td>9 y 2 mo</td>
<td>Corticosteroids, etanercept, tocilizumab, adalimumab, anakinra, abatacept, rituximab, canakinumab</td>
<td>Cushigoid features due to corticosteroids excess, hypertension, severe osteoporosis with vertebral crush fractures, growth failure</td>
</tr>
<tr>
<td>13</td>
<td>2014/CCHMC</td>
<td>F</td>
<td>sJIA</td>
<td>9 mo</td>
<td>4 y 4 mo</td>
<td>Corticosteroids, anakinra, rituximab, tocilizumab, CsA</td>
<td>Overweight due to corticosteroids excess</td>
</tr>
<tr>
<td>14</td>
<td>2015/CCHMC</td>
<td>F</td>
<td>sJIA</td>
<td>12 y</td>
<td>16 y 9 mo</td>
<td>Corticosteroids, adalimumab, tocilizumab, canakinumab, rituximab, MTX, abatacept</td>
<td>Osteoporosis, obesity, glucose intolerance, polycystic ovarian syndrome, nonalcoholic hepatic steatosis</td>
</tr>
<tr>
<td>15</td>
<td>2016/N</td>
<td>F</td>
<td>sJIA</td>
<td>18 mo</td>
<td>11 y</td>
<td>Corticosteroids, MTX, etanercept, anakinra, adalimumab, tocilizumab, infliximab</td>
<td>Corticosteroids-related osteoporosis (impact fracture) and growth failure, elevated serum amyloid A</td>
</tr>
<tr>
<td>16</td>
<td>2016/N</td>
<td>F</td>
<td>sJIA</td>
<td>2 y</td>
<td>5 y</td>
<td>Corticosteroids, MTX, etanercept, anakinra, adalimumab, tocilizumab, infliximab</td>
<td>Poor QOL</td>
</tr>
</tbody>
</table>

ATG, antithymocyte globulin; CCHMC, Cincinnati Children's Hospital Medical Center; CMV, cytomegalovirus; EF, ejection fraction; F, female; FS, fraction of shortening; GOSH, Great Ormond Street Hospital; M, male; N, Newcastle Great North Children’s Hospital; PICU, pediatric intensive care unit; QOL, quality of life; UCLH, University College London Hospital.
Table 2. Transplant characteristics and outcome

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>HLA donor/conditioning</th>
<th>Source: CD34 (×10^6/kg); CD3 (×10^8/kg)</th>
<th>Ne D &gt; 0.5 × 10^9/kg</th>
<th>Chimerism at last follow-up</th>
<th>Complications</th>
<th>Time to stop IS</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>9/10 (1C) mMUD Flu/Mel/Alem</td>
<td>PB: 6.3; 3.2</td>
<td>11</td>
<td>PB/WB: 100%</td>
<td>Grade IV aGVHD (skin and gut); shingles; adenoviremia; EBV virome; BKV encephalitis.</td>
<td>Ongoing at the last follow-up in CR.</td>
<td>Died of sepsis (20 mo post-HSCT).</td>
</tr>
<tr>
<td>2</td>
<td>10/10 MUD Flu/Mel/Alem</td>
<td>BM: N/A</td>
<td>9</td>
<td>N/A</td>
<td>Grade III aGVHD (skin, liver and gut); invasive fungal infection.</td>
<td>Ongoing at the last follow-up</td>
<td>Died of pulmonary hemorrhage 85 d post-HSCT</td>
</tr>
<tr>
<td>3</td>
<td>10/10 MUD Flu/Mel/Alem</td>
<td>PB: 13.83; 7.7</td>
<td>26</td>
<td>PB/WB: 100%; CD19: 100%</td>
<td>CMV pneumonitis + T-cell sequestration; adenoviremia; thrombocytopenia, neutropenia (2× CD34 top-ups), eltrombopag and splenectomy</td>
<td>Off CsA (11 mo), corticosteroids (24 mo)</td>
<td>CR 7 y f/u</td>
</tr>
<tr>
<td>4</td>
<td>10/10 MUD Flu/Mel/Alem</td>
<td>PB: 7.1; 15.5</td>
<td>10</td>
<td>PB/WB: 100%</td>
<td>Adenoviremia, requiring 1×CTLs</td>
<td>7 mo</td>
<td>CR 5 y 10 mo f/u</td>
</tr>
<tr>
<td>5</td>
<td>11/12 MUD Flu/Treo/Alem</td>
<td>PB: 7.1; 2.7</td>
<td>12</td>
<td>PB/WB: 100%</td>
<td>HHV6 enteritis; transient Guillain-Barré syndrome secondary to shingles (VZV)</td>
<td>7 mo</td>
<td>CR; then relapsed at 5 y f/u Episode of shingles (VZV) Polyarthritides (feet, knees, hands, shoulder); uveitis; on tocilizumab and IA corticosteroids; on antidepressants</td>
</tr>
<tr>
<td>6</td>
<td>12/12 MUD Flu/Treo/Alem</td>
<td>PB: 21.2; 5.2</td>
<td>18</td>
<td>CD3: 94%; CD15: 90%; CD19: 61%</td>
<td>Grade II skin aGVHD (skin, transient)</td>
<td>4 mo</td>
<td>CR 3.5 y f/u</td>
</tr>
<tr>
<td>7</td>
<td>10/10 MSD Flu/Treo/Alem</td>
<td>BM: 1.7; 2.6</td>
<td>25</td>
<td>CD3: 67%; CD15: 24%; CD19: 51%</td>
<td>BKV virus hemorrhagic cystitis;</td>
<td>6 mo</td>
<td>CR 2.5 y f/u CMV and adenoviremia</td>
</tr>
<tr>
<td>8</td>
<td>10/10 MUD Flu/Mel/Alem</td>
<td>PB: 12.2; 2.66</td>
<td>13</td>
<td>CD3: 96%; CD15: 95%; CD19: 100%</td>
<td>Autoimmune neutropenia and thrombocytopenia</td>
<td>6 mo</td>
<td>CR 2 y 9 mo f/u</td>
</tr>
<tr>
<td>9</td>
<td>10/10 MSD Flu/Mel/Alem</td>
<td>PB: 26; 5</td>
<td>20</td>
<td>CD3: 55%; CD15: 94%; CD19: 85%</td>
<td>Grade I aGVHD upper gut EBV virome; CMV vireme</td>
<td>7 mo</td>
<td>Developed fevers with raised inflammatory markers. Rx corticosteroids 1 mg/kg. Off IS since 26 mo post-HSCT and in CR. 2 y 4 mo f/u</td>
</tr>
<tr>
<td>10</td>
<td>9/10 (1DQ1) mMUD Flu/Mel/Alem</td>
<td>PB: 6.8; 1.52</td>
<td>65</td>
<td>CD3: &lt;10%; CD15: 0%; CD19: 0%</td>
<td>Pneumomediastinum and pneumothorax.</td>
<td>6 mo</td>
<td>CR 2 y 2 mo f/u</td>
</tr>
<tr>
<td>11</td>
<td>10/10 MUD Flu/Mel/Alem</td>
<td>PB: 9.2; 3</td>
<td>10</td>
<td>PB/WB: 100%</td>
<td>Grade I aGVHD (skin/upper gut) adenoviremia requiring 1× CTLs; Serratia fasciclis; shingles; AVN both hips</td>
<td>10 mo</td>
<td>CR 2 y f/u</td>
</tr>
<tr>
<td>12</td>
<td>10/10 MUD Flu/Treo/Alem</td>
<td>PB: 8.2; 3.3</td>
<td>14</td>
<td>PB/WB: 100%</td>
<td>None</td>
<td>Ongoing at 20 mo post</td>
<td>PR 20 mo f/u</td>
</tr>
<tr>
<td>13</td>
<td>10/10 MSD Flu/Mel/Alem</td>
<td>BM: 19; 0.36</td>
<td>12</td>
<td>PB/WB: 100%</td>
<td>None</td>
<td>6 mo</td>
<td>CR 22 mo f/u</td>
</tr>
<tr>
<td>14</td>
<td>9/10 mMUD Flu/Mel/Alem</td>
<td>PB: 15.4; 2.9</td>
<td>11</td>
<td>PB/WB: 100%</td>
<td>Autoimmune thrombocytopenia Rx rituximab, hence still on immunoglobulin replacement</td>
<td>7 mo</td>
<td>CR 13 mo f/u</td>
</tr>
</tbody>
</table>

AVN, avascular necrosis; BKV, BK virus; BM, bone marrow; CTL, cytotoxic T lymphocyte; EBV, Epstein-Barr virus; Flu/Mel/Alem, fludarabine/melphalan/alemtuzumab; Flu/Treo/Alem, fludarabine/treosulfan/alemtuzumab; f/u, follow-up; IA, intra-articular; mMUD, mismatched unrelated donor; MP, methylprednisolone; MSD, matched sibling donor; MUD, matched unrelated donor; N/A, not available; Ne D > 0.5 × 10^9/kg, number of days to achieve neutrophils >0.5 × 10^9/kg; PB, peripheral blood; PB/WB, peripheral blood/whole blood; Rx, received; VZV, varicella zoster virus.
All patients had hematological recovery. The median time to neutrophil recovery >0.5 × 10^9/L was 13 days (range, 10-65 days), while the median time to platelet recovery >20 × 10^9/L was 15 days (range, 9-87 days).

With a median follow-up of 29 months (range, 2.8-8 years), 14 of 16 patients were alive: patient 1 died of probable sepsis 20 months posttransplant following an elective procedure to replace the right patella while still on immunosuppressive treatment of chronic GVHD and patient 2 died of invasive fungal infection in the context of grade III aGVHD, 85 days posttransplant, giving a transplant related mortality (TRM) of 12.5%.

**Infections.** The incidence of viral infections/reactivation was high; details are reported in Table 2. Three patients developed shingles, 1 patient experienced Guillain-Barré syndrome associated with varicella zoster virus reactivation and HHV6 enteritis, while 6 patients developed adenoviremia requiring antiviral medications or treatment with adenovirus-specific T cells (patient 4 and patient 11). Two patients developed EBV viremia requiring treatment with rituximab (patients 1 and 9) and 2 patients had CMV reactivation leading to pneumonitis in 1 case (patient 3). One patient developed BKV encephalitis (patient 1). There was 1 case each of *Serratia* fasciitis (patient 11) and of infection with atypical mycobacteria (patient 3). Two patients experienced severe bacterial infections and 1 child presented disseminated life-threatening fungal disease (patient 2).

**GVHD.** Three patients experienced grade II-IV acute GVHD (aGVHD). There was 1 patient with extensive chronic GVHD (patient 1) at the last follow-up. On balance, patient 12 and patient 16 were considered to have recurrent disease post-HSCT as both presented with active polyarthritis, but distinguishing recurrent disease from chronic GVHD in this setting can be very difficult.

**JIA outcome and donor engraftment.** The median number of affected joints pretransplant was 12 (range, 3-70 joints) whereas posttransplant 4 patients had active joint inflammation: patient 5 had a reduced number of joints affected (feet, knees, hands, and shoulders) compared with 39 joints affected pretransplant; patient 9 had 1 active joint transiently; patient 12 had a reduced number of joints from almost all joints affected to 8 joints and patient 16 had polyarthritis following cessation of IS as shown in Figure 1. At last follow-up, 11 of 14 surviving patients were in complete remission (symptom-free and off immunosuppressants), 2 of 4 surviving patients with poly-JIA and 9 of 10 with sJIA. Patient 5 achieved complete remission posttransplant sustained after cessation of IS but had relapse of arthritis and uveitis 5 years post-HSCT requiring intra-articular corticosteroids and tocolizumab. Patient 12 had chronic severe active disease prior to HSCT, which was refractory to immunosuppressive treatment: she was immobile, fully dependent on her mother, and unable to take care of herself. After transplant, she experienced a significant clinical improvement: at last follow-up, she was physically active, walking and with no pain, although she was still dependent on corticosteroids and MMF. Patient 9, who had sJIA and MAS prior to his HSCT, presented 22 months following the allo-HSCT with fevers, skin rash, and arthralgia in 1 joint. This was treated with a brief course of corticosteroids, with complete resolution of the symptoms. He was in CR and off immunosuppressant at last follow-up. Patient 16 developed...
requiring 2 CD34+ cell infusions, as well as IVIG, rituximab, eltrombopag and eventually splenectomy; patient 13 developed immune thrombocytopenia requiring rituximab, whereas patient 8 experienced immune-mediated neutropenia and thrombocytopenia treated with IVIG, corticosteroids, rituximab, and MMF. Patient 5 developed severe but transient Guillain-Barré syndrome. Patient 15 developed transient thyrotoxicosis evolving to hypothyroidism.

Discussion

Children affected by JIA can experience significant morbidity associated with poorly controlled disease and long-term immunosuppressive treatment, in particular serious infections, neuropsychiatric adverse events, autoimmunity, and an increased risk of malignancy. Over the past decade, the experience with autologous stem cell transplantation (ASCT) for patients with refractory JIA has produced valuable data. The biological mechanisms by which ASCT works were shown to be not only by the eradication of autoreactive lymphocytes with immunosuppressive conditioning and T-cell depletion, but also importantly by restoration of the chimeric T-cell receptor (TCR) repertoire and CD4+ CD25+ T regulatory cells. Rates of drug-free remission were between 50% and 57%. However, in a prospective follow-up of the initial multicenter study, 12 of 20 patients relapsed between 2 and 16 months posttransplant and 1 patient relapsed 7 years following ASCT. The mechanism of relapse was hypothesized to have occurred due to insufficient lymphoablation and clonally skewed TCR repertoire or due to recurrence of activated effector CD4+ T lymphocytes (autoreactive lymphocytes). Moreover, the initial mortality associated with the procedure was high at 9% as 2 patients died of MAS early post-ASCT and a similar high mortality rate was reported at a later stage from the United Kingdom experience. This high TRM was attributed to the combination of significant T-cell depletion and infection.

Considering that the pathogenesis of sJIA is very similar to known genetic autoinflammatory diseases affecting mostly the innate immune system, there might be a theoretical advantage of allogeneic stem cell transplant compared with ASCT. Allogeneic stem cell transplant in animal models has been shown to generate intrathymic tolerance more effectively when compared with allogeneic transplantation. Moreover, allogeneic stem cell transplantation has the potential for a graft-versus-autoimmune effect, documented in a series of patients who underwent HSCT for hematological conditions and concomitant autoimmune diseases. Somewhat unexpectedly, the results of both the European experience (1984-2007) and a United Kingdom national analysis (1997-2009) of allo-HSCT for severe autoimmune diseases showed 55% CR and 23% PR in the European database, and sustained responses in 60% to 70% of patients undergoing allo-HSCT compared with 30% to 40% of patients undergoing autologous HSCT in the United Kingdom database.

Following our initial report, we describe the outcomes of reduced intensity allogeneic transplantation for JIA in a multicenter cohort of 16 pediatric patients in a 9-year period. With the follow-up duration ranging from 85 days to 8 years, we observed an overall survival of 87.5%. At last follow-up, 11 of 14 surviving patients were in CR (symptom free and off immunosuppressants), 1 was in PR, and 2 had active disease (1 late relapse and 1 relapse after cessation of immunosuppressants).

In this complex cohort of patients where allo-HSCT was performed relatively late in the course of the disease, TRM was expectedly high at 12.5%, but not dissimilar to the TRM reported for autologous
T-cell–depleted HSCT.\textsuperscript{11,13} There was a high incidence of viral infections and/or viral reactivation, not unexpected in the context of in vivo T-cell–depleted transplantation. We did observe the occurrence of secondary autoimmunity post-HSCT, mainly cytopenias, which did not require prolonged treatment as has been previously reported.\textsuperscript{41}

Selecting eligible patients for allo-HSCT earlier in the course of their progressive disease rather than leaving it as the “last resort”\textsuperscript{42,43} could significantly improve the outcome, in particular by reducing morbidity from potentially life-threatening infections and preventing the development of severe joint damage and consequent complications.

For those rare patients presenting with potential life-threatening complications such as pulmonary hypertension and/or MAS\textsuperscript{44} the indication may be more straightforward. However, for patients with otherwise uncomplicated but refractory disease, that is, those not responding to multiple conventional or biologic DMARDs, defining the correct indications for allogeneic transplantation remains a challenge.\textsuperscript{32} At the present time there are several studies assessing potential biomarkers and specific molecular defects associated with a severe disease phenotype and response to therapy.\textsuperscript{45,46} While those are validated, indication for HSCT is defined individually and according to the experience of the center, as this approach is still an experimental therapy.\textsuperscript{42,47} Normalization of raised serum interleukin-18 (IL-18) levels has recently been demonstrated posttransplant, hence serum IL-18 may potentially be a useful biomarker to assess disease activity of sJIA in this context.\textsuperscript{48,49}

Of note, a potential disadvantage of allo-HSCT following a failed autologous procedure is the possibility of adding comorbidities, especially from severe infections (eg, patient 1). The indications for and the role of allo-HSCT for treating children with JIA may be better defined once genetic defects or biomarkers associated with severe phenotypes of the disease are revealed.

**Figure 2.** Engraftment of patients who underwent allogeneic stem cell transplantation at 3, 6, and 12 months and at the last follow-up.
Despite reduced intensity conditioning, all patients engrafted donor cells in all cell lineages except 1 patient who underwent a mismatched unrelated donor transplant and only engrafted donor T cells. It is not known at this stage whether there will be an impact of mixed chimerism on the ongoing remission status of the disease posttransplantation. In this cohort of patients, full donor chimerism was not always associated with remission: 1 patient with 100% donor cell engraftment had only partial response with ongoing inflammation of big joints requiring low-dose corticosteroids and MMF 12 months posttransplant, 2 patients with high-level donor cell engraftment have active disease at last follow-up (1 relapsed late posttransplant [patient 5] and 1 patient relapsed following cessation of IS 6 months posttransplant), whereas another patient with only partial T-cell engraftment remains in CR 17 months posttransplant. The mechanism of remission in the latter patient is possibly due to self-tolerance of autoreactive T cells, mirroring that in the autologous HSCT setting.27 Similar to the results from the ASCT experience, we presume that significant joint damage prior to transplant is not reversible with the procedure even despite full donor chimerism.15

As this was an observational retrospective study, there were limitations relating to the availability of data to fully assess JIA disease activity pre- and post-HSCT using the core set criteria.50 For this study, we were only able to collect data on joint counts and ESR (Figures 1 and 4, respectively).

In conclusion, we show that reduced intensity HSCT for severe, refractory JIA is a safe and effective procedure to rescue patients that did not respond despite being heavily treated, or those who developed complications associated with MAS. However, to reduce TRM and morbidities, mainly infections, we favor considering early HSCT for those eligible patients with a suitable available donor avoiding prolonged use of immunosuppressive medications and preventing severe and potentially irreversible joint damage, and/or treatment-associated burden of disease mainly growth retardation, hypertension, and osteoporosis due to prolonged corticosteroid usage. Prospective studies are warranted to harmonize selection of patients and indications for transplant, to evaluate conditioning regimens that could promote robust engraftment with even lower toxicity, to assess potential biomarkers, and to investigate immunological mechanisms of remission following allo-HSCT.

Clearly, longer follow-up is required to confirm the effectiveness of allo-HSCT for severe, refractory JIA as late relapse has been observed in this setting. As JIA is a complex group of disorders, it is of paramount importance that the follow-up post-HSCT includes a multidisciplinary team (transplant, rheumatology, immunology, and physiotherapy specialties) following standardized methods. This would facilitate better assessment of disease response, better evaluation of the role of HSCT in the therapeutic algorithm, and indicate whether there is any difference in the outcomes between the subtypes of the disease.

Acknowledgments
The authors thank Yasmine Koodun for assistance providing patient data.

This work was supported by the National Institute for Health Research (NIHR) Great Ormond Street Hospital Biomedical Research Centre.

The views expressed are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR, or the Department of Health.

Authorship

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Juliana M. F. Silva, Department of Bone Marrow Transplantation, Great Ormond Street Hospital for Children NHS Trust, Great Ormond St, London WC1N 3JH, United Kingdom; e-mail: juliana.silva@gosh.nhs.uk.

Figure 3. Median T-cell and B-cell counts following allo-HSCT for JIA.
Number of patients with available data at each time point.

Figure 4. ESR pre- and post-HSCT. Data available for 15 patients pre-HSCT; for patients 1, 2, 3, 9, 11, and 16 at 3 months post-HSCT; for patients 1, 6, 9, and 11 at 6 months post-HSCT; for patients 1, 2, 8, 9, and 11 at 9 months post-HSCT, and for patients 1, 2, 6, 9, and 11 at 12 months post-HSCT.
References


